The Joint Corp. Q2 2026 Earnings Recap

The Joint Corp’s Q2 earnings produced little market reaction, reflecting a largely in-line performance without clear surprises on either upside or downside.

Key Takeaways

• Revenue grew 14% year-over-year to $15.2 million, driven by continued refranchising progress and franchise-related income.
• Adjusted EBITDA improved by $1.4 million to $1.5 million, reflecting operating leverage as the company shifts to a capital-light franchisor model.
• Consolidated net income increased to $653,000 from $93,000 in Q2 2025, supported by disciplined capital allocation and improved patient retention.
• Cash flow from operations grew 152% year-over-year to $2.2 million, resulting in $1.9 million free cash flow, benefiting from refranchising and cost control.
• Management highlighted successful refranchising transactions reducing company-owned clinics to just three, positioning for franchise growth but did not provide new organic growth metrics or updated guidance.